<DOC>
	<DOCNO>NCT00119873</DOCNO>
	<brief_summary>The purpose study determine safety immune response experimental HIV vaccine HIV uninfected individual .</brief_summary>
	<brief_title>Safety Immune Response Experimental HIV Vaccine ( VRC-HIVADV014-00-VP ) HIV Uninfected Adults</brief_title>
	<detailed_description>The HIV epidemic major global health challenge . People develop nation limited access life-sustaining antiretrovirals account 95 % 5 million new HIV infection annually . The development safe , effective , widely accessible HIV vaccine paramount area . The adenoviral vector vaccine VRC-HIVADV014-00-VP show elicit CD8 cytotoxic lymphocyte ( CTL ) response believe crucial effective preventive HIV vaccine . The purpose study determine safety immunogenicity VRC-HIVADV014-00-VP HIV uninfected adult . In study , HIV uninfected individual low level pre-existing adenovirus neutralize antibody receive different dos preventive vaccine determine safety , tolerability , immunogenicity . This study last 1 year . Participants randomly assign one two group . At study entry , participant group receive single injection either one two dose adenoviral vector vaccine placebo . Participants record temperature side effect symptom log day vaccination 3 day thereafter . Participants seven clinic visit 12 month . A physical exam , HIV pregnancy prevention counseling , blood urine collection occur visit . Participants also ask side effect may experience medication take .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Have access participate site willing follow duration study Willing receive HIV test result Able understand comply study requirement In good general health Have neutralize adenovirus antibody level less 1:12 ratio Agree use acceptable method contraception least 21 day prior study start duration study . HIV infect Positive hepatitis B surface antigen Positive antihepatitis C virus antibody Prior receipt HIV vaccine Immunosuppressive drug within 168 day prior first vaccination Have receive donate blood within 120 day prior first vaccination Have receive immunoglobulin within 60 day first vaccination Live attenuate vaccine investigational research agent within 30 day prior first vaccination Subunit kill vaccine within 14 day prior first vaccination Current preventive therapeutic antituberculosis ( TB ) treatment Any medical , psychiatric , social condition would interfere study Any occupational responsibility would interfere study Serious adverse reaction vaccine Autoimmune disease Immunodeficiency Active syphilis infection . Participants fully treat syphilis 6 month prior study entry exclude . Asthma . Participants completely resolve childhood asthma exclude . Diabetes mellitus type I II . Participants isolate gestational diabetes exclude . Thyroid disease removal thyroid Blood vessel swell within last 3 year Uncontrolled hypertension Body mass index ( BMI ) 40 high Bleeding disorder Cancer . Participants whose cancer remove unlikely recur study exclude . Seizure disorder . Participants required medication seizure 3 year prior study entry exclude . Removal spleen nonfunctioning spleen Psychiatric condition may interfere study Pregnancy , breastfeeding , plan become pregnant study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>Adenoviridae</keyword>
</DOC>